Business Context and Reporting Period
Company: Herbalife Ltd.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Global nutrition company selling weight management, targeted nutrition, energy, sports, fitness, and outer nutrition products through a network of independent members. Operations are organized into five geographic regions: North America, Latin America, EMEA, Asia Pacific, and China.
Key Financial Metrics
| Metric (in millions) | Q2 2025 | Q2 2024 | 6M 2025 | 6M 2024 |
|---|---|---|---|---|
| Net Sales | $1,259.1 | $1,281.1 | $2,480.8 | $2,545.4 |
| Gross Profit | $982.2 | $998.0 | $1,938.7 | $1,977.3 |
| Gross Margin % | 78.0% | 77.9% | 78.1% | 77.7% |
| Operating Income | $132.6 | $80.4 | $255.4 | $152.3 |
| Net Income (Attributable to Herbalife) | $49.3 | $4.7 | $99.7 | $29.0 |
| Diluted EPS | $0.48 | $0.05 | $0.97 | $0.29 |
| Operating Cash Flow (6M) | $96.2 | $116.3 | $96.2 | $116.3 |
| Cash & Equivalents (End of Period) | $320.9 | $415.3 | $320.9 | $415.3 |
| Total Debt (Carrying Value) | $2,141.5 | $2,260.1 | $2,141.5 | $2,260.1 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 1.7% in Q2 and 2.5% in the first half of 2025 compared to 2024. The decline was driven by unfavorable foreign currency fluctuations and decreased sales volume, partially offset by price increases.
- Profitability Surge: Net income increased 949% in Q2 and 244% in the first half of 2025. This significant improvement was primarily due to a $10.5 million loss on debt extinguishment in Q2 2024 (non-recurring) and a $54.4 million reduction in Selling, General, and Administrative (SG&A) expenses in Q2 2025.
- SG&A Reduction: SG&A expenses dropped significantly due to lower labor and benefits costs, specifically reduced employee retention and separation costs associated with the completion of the Restructuring Program and Transformation Program.
- Debt Management: The company continued to reduce its debt load, redeeming $115.0 million of its 2025 Senior Notes during the first half of 2025. Total debt carrying value decreased by approximately $118.6 million year-over-year.
- Acquisitions: In April 2025, the company acquired assets of Pruvit Ventures (ketone supplements) and Pro2col Health (digital health platform) for approximately $19 million, and acquired a 51% interest in Link BioSciences for $6.5 million.
Guidance, Outlook, and Risks
- Capital Expenditures: Management expects total capital expenditures for the full year 2025 to be between $75 million and $95 million, including investments in the "Herbalife One" digital technology program.
- Restructuring Savings: The Restructuring Program is expected to deliver annual savings of at least $80 million beginning in 2025. The Technology Realignment Program is expected to deliver annual savings of approximately $9 million beginning in 2026.
- Regulatory & Tax Contingencies: The company faces significant tax assessments in Brazil (ICMS and withholding taxes) and India, as well as VAT issues in Mexico. Management does not believe a loss is probable for the majority of these assessments but notes they are subject to litigation. A class action lawsuit regarding distributor classification in California is ongoing.
- Geopolitical Risks: Operations in Russia have been suspended due to inventory depletion and geopolitical conflict. The company monitors inflation, foreign exchange fluctuations, and trade tensions which impact cost structures and pricing.
- Share Repurchases: The previous $1.5 billion share repurchase program expired in February 2024. No open-market repurchases were made in the first half of 2025.
Investor Verification Checklist
- Debt Maturity Wall: Verify the repayment plan for the remaining $147.3 million of 2025 Senior Notes maturing in September 2025 and the $380.0 million outstanding under the 2024 Term Loan B.
- FX Sensitivity: Assess the impact of a strengthening U.S. dollar on future gross margins, given that a significant portion of sales are in local currencies while costs are often in U.S. dollars.
- China Performance: Monitor the China segment, which saw a 7.7% sales decline in the first half of 2025, to determine if volume decreases are stabilizing.
- Tax Resolution: Track the status of the Brazil and India tax litigation, as unfavorable outcomes could result in material charges.
- Acquisition Integration: Evaluate the performance of the newly acquired Pruvit and Pro2col assets and the success of the Pro2col beta launch in North America.